Our favorable outlook for the biotechnology industry remains intact for 2012 and is based on several key drivers
Biotech’s Top and Bottom Ten from 2010
January 5, 2011 By Leave a Comment
At the start of the year, we provided a favorable outlook for the biotechnology industry in 2010 that was based on the same six drivers we proposed for 2009, which included the following: Sector’s defensive characteristics and impact on future economic growth Highest number of annual new product approvals since 2004 Record number of products [...]
Biotech Deal Activity Declines…The Pause that Refreshes?
January 14, 2010 By 1 Comment
* MD Becker Partners reporting live from the JP Morgan Healthcare Conference This week, nearly 6,500 registrants gathered in San Francisco, California for the JP Morgan Healthcare Conference to hear 25-minute presentations from 338 life science companies. For industry executives and investors, the annual event serves as a good barometer for the rest of the [...]
Follow MD Becker Partners